<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7360901\results\search\disease\results.xml">
  <result pre="bold;} span.year {font-family : courier ; font-style : italic;} Neth" exact="Heart" post="JNeth Heart JNetherlands Heart Journal1568-58881876-6250Bohn Stafleu van LoghumHouten pmcid:"/>
  <result pre="{font-family : courier ; font-style : italic;} Neth Heart JNeth" exact="Heart" post="JNetherlands Heart Journal1568-58881876-6250Bohn Stafleu van LoghumHouten pmcid: 73609011475 doi:"/>
  <result pre="courier ; font-style : italic;} Neth Heart JNeth Heart JNetherlands" exact="Heart" post="Journal1568-58881876-6250Bohn Stafleu van LoghumHouten pmcid: 73609011475 doi: 10.1007/s12471-020-01475-1 :"/>
  <result pre="of 2019, aÂ new potentially lethal human coronavirus designated severe" exact="acute" post="respiratory syndrome coronavirusÂ 2 (SARS-CoV-2) emerged in Wuhan, China."/>
  <result pre="2019, aÂ new potentially lethal human coronavirus designated severe acute" exact="respiratory" post="syndrome coronavirusÂ 2 (SARS-CoV-2) emerged in Wuhan, China. The"/>
  <result pre="aÂ new potentially lethal human coronavirus designated severe acute respiratory" exact="syndrome" post="coronavirusÂ 2 (SARS-CoV-2) emerged in Wuhan, China. The pandemic"/>
  <result pre="emergency and an unprecedented socioeconomic crisis. The severity of coronavirus" exact="disease" post="2019 (COVID-19), the illness caused by SARS-CoVâ€‘2, is highly"/>
  <result pre="is presented of the virological assays for detecting ongoing SARS-CoVâ€‘2" exact="infections" post="and the serological tests for SARS-CoV-2-specific antibody detection. Also"/>
  <result pre="COVID-19 with antiviral drugs, immunomodulatory agents and anticoagulants/antithrombotics. Finally, the" exact="cardiovascular" post="manifestations of COVID-19 are briefly touched upon. While there"/>
  <result pre="into COVID-19 raise the hope that aÂ remedy for this" exact="disease" post="will soon be found. COVID-19 will nonetheless have aÂ"/>
  <result pre="supplementary material, which is available to authorized users. Keywords Coronavirus" exact="disease" post="2019 Severe acute respiratory syndrome coronavirus 2 Pandemic Acute"/>
  <result pre="which is available to authorized users. Keywords Coronavirus disease 2019" exact="Severe" post="acute respiratory syndrome coronavirus 2 Pandemic Acute respiratory distress"/>
  <result pre="is available to authorized users. Keywords Coronavirus disease 2019 Severe" exact="acute" post="respiratory syndrome coronavirus 2 Pandemic Acute respiratory distress syndrome"/>
  <result pre="available to authorized users. Keywords Coronavirus disease 2019 Severe acute" exact="respiratory" post="syndrome coronavirus 2 Pandemic Acute respiratory distress syndrome Vaccine"/>
  <result pre="to authorized users. Keywords Coronavirus disease 2019 Severe acute respiratory" exact="syndrome" post="coronavirus 2 Pandemic Acute respiratory distress syndrome Vaccine Antiviral"/>
  <result pre="Coronavirus disease 2019 Severe acute respiratory syndrome coronavirus 2 Pandemic" exact="Acute respiratory distress syndrome" post="Vaccine Antiviral drug Introduction Coronaviruses (CoVs) were first described"/>
  <result pre="disease 2019 Severe acute respiratory syndrome coronavirus 2 Pandemic Acute" exact="respiratory" post="distress syndrome Vaccine Antiviral drug Introduction Coronaviruses (CoVs) were"/>
  <result pre="Severe acute respiratory syndrome coronavirus 2 Pandemic Acute respiratory distress" exact="syndrome" post="Vaccine Antiviral drug Introduction Coronaviruses (CoVs) were first described"/>
  <result pre="designated Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Deltacoronavirus. CoVs generally have aÂ" exact="limited" post="host range and, with aÂ few exceptions, cause either"/>
  <result pre="limited host range and, with aÂ few exceptions, cause either" exact="respiratory" post="or enteric infections in mammals and birds. Until recently,"/>
  <result pre="and, with aÂ few exceptions, cause either respiratory or enteric" exact="infections" post="in mammals and birds. Until recently, six different human"/>
  <result pre="human CoVs were distinguished, all of which primarily infect the" exact="respiratory" post="tract (Tab.Â 1). Of these viruses, HCoV-229E, HCoV-HKU1, HCoV-OC43"/>
  <result pre="for some 10â€&quot;15% of the annual common colds [3]. Whereas" exact="infections" post="with these viruses usually take aÂ mild course this"/>
  <result pre="take aÂ mild course this is not the case for" exact="infections" post="with severe acute respiratory syndrome (SARS)-CoV and Middle East"/>
  <result pre="course this is not the case for infections with severe" exact="acute" post="respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV,"/>
  <result pre="this is not the case for infections with severe acute" exact="respiratory" post="syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, for"/>
  <result pre="is not the case for infections with severe acute respiratory" exact="syndrome" post="(SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, for which"/>
  <result pre="infections with severe acute respiratory syndrome (SARS)-CoV and Middle East" exact="respiratory" post="syndrome (MERS)-CoV, for which case-fatality rates of ~10 and"/>
  <result pre="with severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory" exact="syndrome" post="(MERS)-CoV, for which case-fatality rates of ~10 and ~35%,"/>
  <result pre="ID(s)â€&quot;year /Country of origin Genome size /GenBank Acc. No Receptor" exact="Disease" post="Alphacoronavirus HCoV-229E 4285768â€&quot;1966 United States of America 27,317 nts"/>
  <result pre="the new virus was named SARS-CoVâ€‘2, which stands for severe" exact="acute" post="respiratory syndrome coronavirusÂ 2 [7], and the accompanying disease"/>
  <result pre="new virus was named SARS-CoVâ€‘2, which stands for severe acute" exact="respiratory" post="syndrome coronavirusÂ 2 [7], and the accompanying disease was"/>
  <result pre="virus was named SARS-CoVâ€‘2, which stands for severe acute respiratory" exact="syndrome" post="coronavirusÂ 2 [7], and the accompanying disease was designated"/>
  <result pre="severe acute respiratory syndrome coronavirusÂ 2 [7], and the accompanying" exact="disease" post="was designated coronavirus disease 2019 (COVID-19). Like SARS-CoV and"/>
  <result pre="coronavirusÂ 2 [7], and the accompanying disease was designated coronavirus" exact="disease" post="2019 (COVID-19). Like SARS-CoV and MERS-CoV, SARS-CoVâ€‘2 is assumed"/>
  <result pre="SARS-CoV and MERS-CoV from bats to humans likely occurred via" exact="intermediate" post="hosts (presumably civet cats in the case of SARS-CoV"/>
  <result pre="of SARS-CoVâ€‘2 from bats to humans probably also involved an" exact="intermediate" post="host. Whether pangolins have acted as such, as initially"/>
  <result pre="genetic material) in combination with their high replication rate (i.e." exact="short" post="generation time). As aÂ consequence, the genomes of RNA"/>
  <result pre="coat or envelope (Fig.Â 1; [10]). The core contains the" exact="viral" post="genome complexed with the nucleocapsidÂ (N)Â protein. CoV genomes"/>
  <result pre="the SÂ protein by transmembrane serine proteaseÂ 2 (TMPRSS2), the" exact="viral" post="envelope fuses with the plasma membrane of the target"/>
  <result pre="of the target cell, resulting in the delivery of the" exact="viral" post="genome inside the cell (Fig.Â 2; [11, 12]). Alternatively,"/>
  <result pre="endosomal protease cathepsinÂ L, which initiates the fusion of the" exact="viral" post="envelope with the lipid bilayer of the endosome, causing"/>
  <result pre="lipid bilayer of the endosome, causing the release of the" exact="viral" post="genome into the cytoplasm of the cell. AÂ recent"/>
  <result pre="produces 16Â different nonstructural proteins (nsps), which together form the" exact="viral" post="replicase complex [14]. This complex makes aÂ complementary copy"/>
  <result pre="complex [14]. This complex makes aÂ complementary copy of the" exact="viral" post="RNA genome called the antigenome [(âˆ’)gRNA], which serves as"/>
  <result pre="sequence complementary to theÂ 5â€™ (i.e. left) end of the" exact="viral" post="genome. These negative-strand sgRNAs are subsequently transcribed to produce"/>
  <result pre="(i.e. nucleocapsids) associate with membranes of the endoplasmic reticulum (ER)-Golgi" exact="intermediate" post="compartment (ERGIC) in which the S, M and EÂ"/>
  <result pre="to aÂ global case-fatality rate of ~6%. Due to the" exact="limited" post="testing capacity in many countries, especially at the beginning"/>
  <result pre="higher. As aÂ consequence, the true fatality rate will be" exact="lower" post="too. Yet, excess mortality data indicate that the number"/>
  <result pre="die from COVID-19 than females and mortality in Caucasians is" exact="lower" post="than in the other races [19, 20]. Recently, blood"/>
  <result pre="been identified as aÂ risk factor for acquiring COVID-19 with" exact="respiratory" post="failure, i.e. blood group OÂ and AÂ are associated"/>
  <result pre="blood group OÂ and AÂ are associated with, respectively, aÂ" exact="lower" post="and higher risk of acquiring severe COVID-19 than the"/>
  <result pre="associated with aÂ higher risk of COVID-19 hospital death, including" exact="cardiovascular disease," post="diabetes, (haematological) cancer, hypertension and respiratory disease [19, 20]"/>
  <result pre="of COVID-19 hospital death, including cardiovascular disease, diabetes, (haematological) cancer," exact="hypertension" post="and respiratory disease [19, 20] although after adjustment for"/>
  <result pre="hospital death, including cardiovascular disease, diabetes, (haematological) cancer, hypertension and" exact="respiratory" post="disease [19, 20] although after adjustment for multiple variables"/>
  <result pre="death, including cardiovascular disease, diabetes, (haematological) cancer, hypertension and respiratory" exact="disease" post="[19, 20] although after adjustment for multiple variables the"/>
  <result pre="20] although after adjustment for multiple variables the association with" exact="high blood pressure" post="was lost and with chronic heart disease was rather"/>
  <result pre="the association with high blood pressure was lost and with" exact="chronic" post="heart disease was rather weak (HR 1.27) [19]. This"/>
  <result pre="association with high blood pressure was lost and with chronic" exact="heart" post="disease was rather weak (HR 1.27) [19]. This illustrates"/>
  <result pre="with high blood pressure was lost and with chronic heart" exact="disease" post="was rather weak (HR 1.27) [19]. This illustrates the"/>
  <result pre="interpreting the results of univariate analyses. SARS-CoV-2 transmission In the" exact="absence of" post="aÂ SARS-CoVâ€‘2 vaccine and protective immunity resulting from infections"/>
  <result pre="absence of aÂ SARS-CoVâ€‘2 vaccine and protective immunity resulting from" exact="infections" post="with endemic human CoVs, current efforts to bring the"/>
  <result pre="number (R0), which is defined as the expected number of" exact="secondary" post="cases produced by aÂ typical infected individual during the"/>
  <result pre="cases produced by aÂ typical infected individual during the entire" exact="infectious" post="period in aÂ completely susceptible (i.e. non-immune) population and"/>
  <result pre="(i.e. non-immune) population and without any deliberate actions to reduce" exact="disease" post="transmission. Based on early transmission dynamics in Wuhan, Li"/>
  <result pre="confidence interval (CI) 1.4â€&quot;3.9) [22]. Since COVID-19 is primarily aÂ" exact="respiratory" post="infection, respiratory droplets produced (in decreasing numbers) by sneezing,"/>
  <result pre="(CI) 1.4â€&quot;3.9) [22]. Since COVID-19 is primarily aÂ respiratory infection," exact="respiratory" post="droplets produced (in decreasing numbers) by sneezing, coughing, singing,"/>
  <result pre="main sources of virus transmission. AÂ treacherous aspect of SARS-CoVâ€‘2" exact="infections" post="is the presymptomatic transmission of the virus, which may"/>
  <result pre="(RT-qPCR) analysis (see below) in stool and sewage, and occasionally" exact="infectious" post="virus has been recovered from faecal samples [24, 25]."/>
  <result pre="in enterocytes of human small intestinal organoids [26], and the" exact="viral" post="NÂ has been detected by immunofluorescence microscopy in the"/>
  <result pre="immunofluorescence microscopy in the cytoplasm of gastric, duodenal and rectal" exact="epithelial" post="cells but not in oesophageal epithelial cells of endoscopic"/>
  <result pre="gastric, duodenal and rectal epithelial cells but not in oesophageal" exact="epithelial" post="cells of endoscopic biopsies [27]. This raises the possibility"/>
  <result pre="and minks have been shown to be permissive to SARS-CoVâ€‘2" exact="infection" post="(see, for example, [28]) and evidence has been obtained"/>
  <result pre="the Electronic Supplementary Material. Clinical manifestations The outcome of SARS-CoVâ€‘2" exact="infections" post="is highly variable, which may relate to several factors"/>
  <result pre="highly variable, which may relate to several factors including (1)Â" exact="infectious" post="dose, (2)Â general health of the infected individual and"/>
  <result pre="case-fatality rate of 2.3% [30]. In mildly affected individuals the" exact="infection" post="remains largely restricted to the upper respiratory tract, while"/>
  <result pre="mildly affected individuals the infection remains largely restricted to the" exact="upper" post="respiratory tract, while in seriously ill patients it subsequently"/>
  <result pre="affected individuals the infection remains largely restricted to the upper" exact="respiratory" post="tract, while in seriously ill patients it subsequently spreads"/>
  <result pre="while in seriously ill patients it subsequently spreads to the" exact="lower" post="respiratory tract and, from there, possibly to other organs."/>
  <result pre="in seriously ill patients it subsequently spreads to the lower" exact="respiratory" post="tract and, from there, possibly to other organs. The"/>
  <result pre="seriously affected individuals suffer from pneumonia, accompanied by progressive dyspnoea," exact="chest" post="pain, haemoptysis, crackles and/or respiratory insufficiency. In the most"/>
  <result pre="pneumonia, accompanied by progressive dyspnoea, chest pain, haemoptysis, crackles and/or" exact="respiratory" post="insufficiency. In the most severe cases of COVID-19, the"/>
  <result pre="respiratory insufficiency. In the most severe cases of COVID-19, the" exact="pneumonia" post="develops into acute respiratory distress syndrome (ARDS), which may"/>
  <result pre="the most severe cases of COVID-19, the pneumonia develops into" exact="acute" post="respiratory distress syndrome (ARDS), which may lead directly to"/>
  <result pre="most severe cases of COVID-19, the pneumonia develops into acute" exact="respiratory" post="distress syndrome (ARDS), which may lead directly to respiratory"/>
  <result pre="cases of COVID-19, the pneumonia develops into acute respiratory distress" exact="syndrome" post="(ARDS), which may lead directly to respiratory failure and"/>
  <result pre="acute respiratory distress syndrome (ARDS), which may lead directly to" exact="respiratory" post="failure and is aÂ major cause of COVID-19-related death."/>
  <result pre="hypercytokinaemia (cytokine storm) induced by the virus and, together with" exact="secondary" post="microbial infections (e.g. due to loss of intestinal epithelial"/>
  <result pre="storm) induced by the virus and, together with secondary microbial" exact="infections" post="(e.g. due to loss of intestinal epithelial barrier integrity),"/>
  <result pre="with secondary microbial infections (e.g. due to loss of intestinal" exact="epithelial" post="barrier integrity), can culminate in sepsis and end-organ dysfunction"/>
  <result pre="for this is/are unclear. Due to the higher incidence of" exact="respiratory" post="infections, the innate immune system of children may be"/>
  <result pre="cytokine storm due to vigorous replication of SARS-CoVâ€‘2 in the" exact="lower" post="airways. Alternatively, in children replication of SARS-CoVâ€‘2 could be"/>
  <result pre="of SARS-CoVâ€‘2 could be suppressed by the presence of other" exact="respiratory" post="viruses. Also, airway epithelial cells of children may be"/>
  <result pre="suppressed by the presence of other respiratory viruses. Also, airway" exact="epithelial" post="cells of children may be less permissive to SARS-CoVâ€‘2,"/>
  <result pre="children may be less permissive to SARS-CoVâ€‘2, e.g. because of" exact="lower" post="ACE2 expression levels [35]. The average incubation period of"/>
  <result pre="the dominant findings and mostly involved the periphery of the" exact="lower" post="halves of both lungs [39]. Computed tomography (CT) scans"/>
  <result pre="lung segments, respectively. CT image abnormalities rapidly evolved from predominantly" exact="focal" post="unilateral to diffuse bilateral ground-glass opacities that progressed to"/>
  <result pre="segments, respectively. CT image abnormalities rapidly evolved from predominantly focal" exact="unilateral" post="to diffuse bilateral ground-glass opacities that progressed to or"/>
  <result pre="CT image abnormalities rapidly evolved from predominantly focal unilateral to" exact="diffuse" post="bilateral ground-glass opacities that progressed to or co-existed with"/>
  <result pre="image abnormalities rapidly evolved from predominantly focal unilateral to diffuse" exact="bilateral" post="ground-glass opacities that progressed to or co-existed with consolidations"/>
  <result pre="For more information on this topic, see [41]. While the" exact="respiratory" post="tract is the primary target of SARS-CoVâ€‘2, the clinical"/>
  <result pre="this topic, see [41]. While the respiratory tract is the" exact="primary" post="target of SARS-CoVâ€‘2, the clinical symptoms mentioned above show"/>
  <result pre="symptoms mentioned above show that other organs/organ systems, including the" exact="cardiovascular" post="system, the digestive tract, the liver, the kidney, the"/>
  <result pre="cardiovascular system, the digestive tract, the liver, the kidney, the" exact="brain" post="and the eyes, can also be affected by COVID-19"/>
  <result pre="all extrarespiratory manifestations of COVID-19 are necessarily caused by direct" exact="viral" post="injury but may also be the consequence of the"/>
  <result pre="neuroendocrine imbalance and other pathophysiological changes induced by the airway" exact="infection" post="[43]. For information on the clinical management of (severe)"/>
  <result pre="intended for low- and middle-income countries, the Clinical Care for" exact="Severe" post="Acute Respiratory Infection Toolkit of the World Health Organization"/>
  <result pre="for low- and middle-income countries, the Clinical Care for Severe" exact="Acute" post="Respiratory Infection Toolkit of the World Health Organization is"/>
  <result pre="low- and middle-income countries, the Clinical Care for Severe Acute" exact="Respiratory" post="Infection Toolkit of the World Health Organization is another"/>
  <result pre="and middle-income countries, the Clinical Care for Severe Acute Respiratory" exact="Infection" post="Toolkit of the World Health Organization is another excellent"/>
  <result pre="the World Health Organization is another excellent resource for managing" exact="adult" post="and paediatric patients with severe forms of COVID-19 (https://www.who.int/publications/i/item/clinical-care-of-severe-acute-respiratory-infections-tool-kit)."/>
  <result pre="the Electronic Supplementary Material. In the large majority of persons," exact="infection" post="with SARS-CoVâ€‘2 is rapidly and efficiently controlled by the"/>
  <result pre="by the immune system and remains (largely) confined to the" exact="upper" post="respiratory tract. As aÂ consequence, these people develop no"/>
  <result pre="the immune system and remains (largely) confined to the upper" exact="respiratory" post="tract. As aÂ consequence, these people develop no or"/>
  <result pre="disease. However, in aÂ small percentage of infected individuals the" exact="lower" post="respiratory tract also becomes infected, accompanied by hyperinflammation and"/>
  <result pre="However, in aÂ small percentage of infected individuals the lower" exact="respiratory" post="tract also becomes infected, accompanied by hyperinflammation and overactivation"/>
  <result pre="the virus and by the immune system to the airway" exact="epithelial" post="cells and the underlying endothelial cells, the alveolar-capillary barrier"/>
  <result pre="underlying endothelial cells, the alveolar-capillary barrier is broken, resulting in" exact="vascular" post="leakage, alveolar oedema/collapse and ARDS. This may be followed"/>
  <result pre="cause death as aÂ result of multi-organ damage/failure due to" exact="secondary" post="SARS-CoVâ€‘2 and bacterial infections and immune-mediated mechanisms. Although detailed"/>
  <result pre="aÂ result of multi-organ damage/failure due to secondary SARS-CoVâ€‘2 and" exact="bacterial infections" post="and immune-mediated mechanisms. Although detailed knowledge about the interactions"/>
  <result pre="result of multi-organ damage/failure due to secondary SARS-CoVâ€‘2 and bacterial" exact="infections" post="and immune-mediated mechanisms. Although detailed knowledge about the interactions"/>
  <result pre="are thought to play an important role in limiting the" exact="viral infection" post="(to the upper respiratory tract). Based on previous research"/>
  <result pre="thought to play an important role in limiting the viral" exact="infection" post="(to the upper respiratory tract). Based on previous research"/>
  <result pre="an important role in limiting the viral infection (to the" exact="upper" post="respiratory tract). Based on previous research on SARS-CoV and"/>
  <result pre="important role in limiting the viral infection (to the upper" exact="respiratory" post="tract). Based on previous research on SARS-CoV and MERS-CoV"/>
  <result pre="on SARS-CoV and MERS-CoV and various animal models of virus-induced" exact="acute" post="lung injury as well as haematological and biochemical laboratory"/>
  <result pre="the following scenarios can be envisioned [33, 34, 48, 49]." exact="Infection" post="of upper airway epithelial cells, recognition/uptake of SARS-CoVâ€‘2 particles"/>
  <result pre="scenarios can be envisioned [33, 34, 48, 49]. Infection of" exact="upper" post="airway epithelial cells, recognition/uptake of SARS-CoVâ€‘2 particles by dendritic"/>
  <result pre="be envisioned [33, 34, 48, 49]. Infection of upper airway" exact="epithelial" post="cells, recognition/uptake of SARS-CoVâ€‘2 particles by dendritic cells and"/>
  <result pre="resident macrophages and activation of the complement system in the" exact="upper" post="airways trigger the local production and release of pro-inflammatory"/>
  <result pre="natural killer (NK) cells and lymphocytes to the site(s) of" exact="infection" post="and participate in the activation of these immune cells."/>
  <result pre="cells. In the case of an adequate immune response, the" exact="virus infection" post="is subsequently cleared by the concerted action of innate"/>
  <result pre="In the case of an adequate immune response, the virus" exact="infection" post="is subsequently cleared by the concerted action of innate"/>
  <result pre="immune response overshoots, aÂ viscous cycle is induced of further" exact="pulmonary" post="accumulation of immune cells, production of more pro-inflammatory factors"/>
  <result pre="severe COVID-19, but less so in patients with mild disease," exact="lymphopenia" post="is commonly observed, with drastically reduced numbers of BÂ"/>
  <result pre="In general, neutrophil count and neutrophil-to-lymphocyte ratio positively correlate with" exact="disease" post="severity and aÂ worse clinical outcome [51]. In addition,"/>
  <result pre="functional exhaustion, the extent of which is directly proportional to" exact="disease" post="severity. During recovery from COVID-19, the numbers of BÂ"/>
  <result pre="for 6Â weeks after the onset of fever in 19Â" exact="adult" post="patients with RT-qPCR-confirmed COVID-19 [53]. Average SARS-CoV-2-specific IgA (i.e."/>
  <result pre="for COVID-19 fall into two categories: (1)Â tests to detect" exact="viral" post="components, i.e. SARS-CoVâ€‘2 RNA or protein; (2)Â assays to"/>
  <result pre="measure adaptive immunity (i.e. antibodies and TÂ lymphocytes) against SARS-CoVâ€‘2" exact="infection" post="[56, 57]. Although not specific, radiography to visualise lung"/>
  <result pre="SARS-CoVâ€‘2 infection [56, 57]. Although not specific, radiography to visualise" exact="lung disease," post="biomarker analysis to assess tissue/organ damage and inflammation, electron"/>
  <result pre="the diagnosis of COVID-19. Virological tests RT-qPCR-based laboratory assays on" exact="upper" post="or lower respiratory tract samples are presently the standard"/>
  <result pre="of COVID-19. Virological tests RT-qPCR-based laboratory assays on upper or" exact="lower" post="respiratory tract samples are presently the standard tests to"/>
  <result pre="COVID-19. Virological tests RT-qPCR-based laboratory assays on upper or lower" exact="respiratory" post="tract samples are presently the standard tests to detect"/>
  <result pre="by an enzyme called reverse transcriptase, the logarithmic amplification of" exact="viral" post="sequences in aÂ so-called thermocycler using aÂ thermostable DNA"/>
  <result pre="samples, SARS-CoVâ€‘2 RNA is also frequently detected in faeces (reflecting" exact="infection" post="of the gastrointestinal tract), occasionally in blood samples (indicative"/>
  <result pre="and rarely in urine. An alternative method to confirm active" exact="infections" post="is by aÂ sandwich enzyme-linked immunosorbent assay (ELISA; Fig.Â"/>
  <result pre="sandwich enzyme-linked immunosorbent assay (ELISA; Fig.Â 3a). This assay detects" exact="viral" post="protein (i.e. antigen) in clinical specimens after lysis of"/>
  <result pre="early infections, the amount of SARS-CoVâ€‘2 in specimens from the" exact="upper" post="part of the respiratory tract may be too low"/>
  <result pre="of SARS-CoVâ€‘2 in specimens from the upper part of the" exact="respiratory" post="tract may be too low to be detected and"/>
  <result pre="infected with SARS-CoVâ€‘2 but also can be used for monitoring" exact="disease" post="progression (by taking samples at different sites), to identify"/>
  <result pre="SARS-CoVâ€‘2 varies between individuals. This may relate to differences in" exact="infectious" post="dose but also be the result of inherited and"/>
  <result pre="infectious dose but also be the result of inherited and" exact="acquired" post="differences in their immune system. In most studies, IgM,"/>
  <result pre="similar to those of the antigen detection assays except that" exact="viral" post="proteins (most SÂ or N, but sometimes also whole"/>
  <result pre="also be used for assessment of immunity resulting from natural" exact="infection" post="or active immunisation. However, it is not yet clear"/>
  <result pre="respect, virus neutralisation assays (e.g. plaque reduction and tissue culture" exact="infectious" post="dose assays) may be more informative. In these cell"/>
  <result pre="to determine whether the serum contains antibodies that can inhibit" exact="virus infection." post="AÂ comprehensive overview of (1)Â diagnostic tests, (2)Â performance"/>
  <result pre="SARS-CoVâ€‘2 could be completely eradicated by strict isolation of all" exact="infectious" post="sources similar to the extinction of aÂ predator in"/>
  <result pre="sources similar to the extinction of aÂ predator in the" exact="absence of" post="prey. However, in practice such an approach seems unfeasible"/>
  <result pre="effective SARS-CoVâ€‘2 vaccine (see https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=1804775590 for an overview) to block" exact="infection" post="or, at least, mitigate the consequences of infection. Although"/>
  <result pre="particles inactivated by chemical treatment or high-energy radiation, (2)Â non-replicating" exact="viral" post="vectors directing the expression of one or more SARS-CoVâ€‘2"/>
  <result pre="virus-like particles (i.e. assemblies of one or more of the" exact="viral" post="envelope proteins often with aÂ lipid envelope), (4)Â mRNA"/>
  <result pre="envelope), (4)Â mRNA or plasmid DNA encoding one or more" exact="viral" post="proteins (in particular the SÂ protein as the principal"/>
  <result pre="trimeric form and (6)Â vaccines based on synthetic peptides representing" exact="viral" post="antigenic determinants/epitopes. As these â€˜deadâ€™ vaccines are generally less"/>
  <result pre="of an adjuvant may not be needed for the non-replicating" exact="viral" post="vector- and nucleic-acid-based vaccines, as these vaccines will mediate"/>
  <result pre="they can be produced in large amounts in aÂ relatively" exact="short" post="time. The replicating vaccines comprise (1)Â attenuated versions of"/>
  <result pre="in cultured cells or by genetic engineering and (2)Â replicating" exact="viral" post="vectors encoding one or more SARS-CoVâ€‘2 antigens. Although â€˜liveâ€™"/>
  <result pre="â€˜liveâ€™ vaccines usually confer more durable and robust protection against" exact="disease" post="than â€˜dead vaccinesâ€™, their development time is generally much"/>
  <result pre="applying live vaccines directed against, for example, tuberculosis, poliovirus or" exact="measles" post="virus may reduce the susceptibility to SARS-CoVâ€‘2 infections and"/>
  <result pre="for example, tuberculosis, poliovirus or measles virus may reduce the" exact="susceptibility to" post="SARS-CoVâ€‘2 infections and the severity of COVID-19 [48]. Despite"/>
  <result pre="poliovirus or measles virus may reduce the susceptibility to SARS-CoVâ€‘2" exact="infections" post="and the severity of COVID-19 [48]. Despite the urgent"/>
  <result pre="complement receptors present at their surface. This antibody-dependent enhancement of" exact="infection" post="has previously been observed for feline infectious peritonitis virus"/>
  <result pre="antibody-dependent enhancement of infection has previously been observed for feline" exact="infectious" post="peritonitis virus (FIPV) in cats vaccinated with aÂ recombinant"/>
  <result pre="enhancement of infection has previously been observed for feline infectious" exact="peritonitis" post="virus (FIPV) in cats vaccinated with aÂ recombinant poxvirus"/>
  <result pre="2Â TH (Th2) response, resulting in Th2-driven immunopathology accompanied by" exact="pulmonary" post="eosinophilia, as observed with certain experimental SARS-CoV and MERS-CoV"/>
  <result pre="will be important to establish the duration of protection from" exact="disease" post="following vaccination against COVID-19. Finally, one has to consider"/>
  <result pre="based on current SARS-CoVâ€‘2 variants will provide no or only" exact="partial" post="protection against future strains of the virus or other"/>
  <result pre="aÂ rigorous surveillance and containment programme can lead to the" exact="complete" post="eradication of aÂ viral disease, as demonstrated for smallpox."/>
  <result pre="containment programme can lead to the complete eradication of aÂ" exact="viral" post="disease, as demonstrated for smallpox. Which type(s) of vaccine"/>
  <result pre="vaccination, another strategy consists of thwarting the virus once an" exact="infection" post="has revealed itself by the administration of antiviral drugs"/>
  <result pre="exert their beneficial effect by inhibiting crucial steps in the" exact="viral" post="life cycle like receptor binding, envelope fusion, polyprotein processing"/>
  <result pre="of angiotensin II/angiotensin-(1â€&quot;7)Â balance [66] and thereby help to preserve" exact="pulmonary" post="vascular integrity. Sâ€‘protein-specific neutralising monoclonal antibodies can either interfere"/>
  <result pre="angiotensin II/angiotensin-(1â€&quot;7)Â balance [66] and thereby help to preserve pulmonary" exact="vascular" post="integrity. Sâ€‘protein-specific neutralising monoclonal antibodies can either interfere with"/>
  <result pre="the virus to target cells or prevent fusion of the" exact="viral" post="envelope with the plasma membrane or the membrane of"/>
  <result pre="the plasma membrane or the membrane of endosomes. Merging of" exact="viral" post="and cellular membranes and subsequent release of the viral"/>
  <result pre="of viral and cellular membranes and subsequent release of the" exact="viral" post="genome into the host cell cytoplasm may also be"/>
  <result pre="which may result in aÂ torsades de pointes type of" exact="ventricular tachycardia." post="Apart from using monoclonal antibodies for passive immunisation purposes"/>
  <result pre="be employed to protect newly infected individuals from developing severe" exact="disease" post="[69]. SARS-CoVâ€‘2 replication can also be inhibited by treatment"/>
  <result pre="interfere with the RNA-dependent RNA synthesis needed to amplify the" exact="viral" post="genome and to produce the subgenomic mRNAs. Nucleoside analogues"/>
  <result pre="in the processing of the SARS-CoVâ€‘2 polyproteins that produce the" exact="viral" post="replication and transcription complexes (Figs.Â 1 andÂ 2). Accordingly,"/>
  <result pre="2). Accordingly, clinical trials have been initiated with the human" exact="immunodeficiency" post="(HIV) protease inhibitor combination lopinavir/ritonavir. The in vivo effectiveness"/>
  <result pre="small interfering RNAs or siRNAs) that are binding/complementary to the" exact="viral" post="genome and promote its degradation. By simultaneous treatment of"/>
  <result pre="genetic code through mutation. An alternative to the inhibition of" exact="viral" post="proteins/processes is the suppression of host cell factors/processes required"/>
  <result pre="in the (1)Â development of early innate immune responses to" exact="viral" post="infections, (2)Â activation of subsequent adaptive immune responses and"/>
  <result pre="finding that they can increase ACE2 expression in human airway" exact="epithelial" post="cells [72]. In general, in patients at risk of"/>
  <result pre="[72]. In general, in patients at risk of developing severe" exact="disease" post="following infection with SARS-CoVâ€‘2, antiviral drug therapy should be"/>
  <result pre="general, in patients at risk of developing severe disease following" exact="infection" post="with SARS-CoVâ€‘2, antiviral drug therapy should be started as"/>
  <result pre="with. Similar to what has been found for HIV and" exact="hepatitis" post="CÂ virus, combining different antiviral drugs may have additive"/>
  <result pre="have additive or synergistic effects. Antiviral drug cocktails will also" exact="lower" post="the risk of the selection of SARS-CoVâ€‘2 variants with"/>
  <result pre="Antiviral drugs may also be employed as prophylactics to prevent" exact="infection" post="or to reduce virus shedding and thereby the risk"/>
  <result pre="are positively correlated with the serum levels of (1)Â positive" exact="acute" post="phase proteins (e.g. Câ€‘reactive protein (CRP), ferritin and the"/>
  <result pre="chemokines (e.g. Câ€‘C motif chemokineÂ 2 (CCL2), also known as" exact="monocyte" post="chemoattractant proteinÂ 1 (MCP1); and Câ€‘Xâ€‘C motif chemokineÂ 10"/>
  <result pre="vigilant for drug-induced organ toxicity, especially of the liver, brain," exact="heart" post="and kidney, and for (ventricular) arrhythmias. Anticoagulants Multiple recent"/>
  <result pre="liver, brain, heart and kidney, and for (ventricular) arrhythmias. Anticoagulants" exact="Multiple" post="recent studies have identified venous and arterial thrombosis secondary"/>
  <result pre="arrhythmias. Anticoagulants Multiple recent studies have identified venous and arterial" exact="thrombosis" post="secondary to SARS-CoVâ€‘2 infection as aÂ major complication of"/>
  <result pre="Anticoagulants Multiple recent studies have identified venous and arterial thrombosis" exact="secondary" post="to SARS-CoVâ€‘2 infection as aÂ major complication of COVID-19,"/>
  <result pre="studies have identified venous and arterial thrombosis secondary to SARS-CoVâ€‘2" exact="infection" post="as aÂ major complication of COVID-19, which likely contributes"/>
  <result pre="rate [77, 78]. The pathophysiological mechanisms involved in the COVID-19-associated" exact="coagulopathy" post="are incompletely understood. Factors that may contribute to the"/>
  <result pre="coagulopathy are incompletely understood. Factors that may contribute to the" exact="thrombophilia" post="observed in severely ill COVID-19 patients include the following:"/>
  <result pre="prothrombotic antiphospholipid antibodies; (6)Â immobility-associated reduction of blood flow; (7)Â" exact="hypoxia" post="due to respiratory impairment resulting from SARS-CoV-2-induced lung injury"/>
  <result pre="(6)Â immobility-associated reduction of blood flow; (7)Â hypoxia due to" exact="respiratory" post="impairment resulting from SARS-CoV-2-induced lung injury [79â€&quot;81]. Based on"/>
  <result pre="SARS-CoV-2-induced lung injury [79â€&quot;81]. Based on the high incidence of" exact="venous thromboembolism," post="myocardial infarction and stroke among COVID-19 patients and the"/>
  <result pre="injury [79â€&quot;81]. Based on the high incidence of venous thromboembolism," exact="myocardial infarction" post="and stroke among COVID-19 patients and the mortality-reducing effect"/>
  <result pre="on the high incidence of venous thromboembolism, myocardial infarction and" exact="stroke" post="among COVID-19 patients and the mortality-reducing effect of empirical"/>
  <result pre="therapeutic anticoagulation with heparin in COVID-19 patients with aÂ sepsis-induced" exact="coagulopathy" post="score â‰¥4 [82], clinical trials have been initiated to"/>
  <result pre="to investigate the impact of (different doses) of antithrombotics on" exact="disease" post="outcome [79]. In addition, recommendations have been formulated for"/>
  <result pre="Cardiovascular manifestations As already mentioned above, albeit patients with pre-existing" exact="cardiovascular disease" post="(CVD) may not be more susceptible to contracting SARS-CoVâ€‘2"/>
  <result pre="manifestations As already mentioned above, albeit patients with pre-existing cardiovascular" exact="disease" post="(CVD) may not be more susceptible to contracting SARS-CoVâ€‘2"/>
  <result pre="patients may be directly related to or coincident with their" exact="cardiovascular" post="comorbidities. Although COVID-19 primarily disrupts the respiratory system, the"/>
  <result pre="coincident with their cardiovascular comorbidities. Although COVID-19 primarily disrupts the" exact="respiratory" post="system, the disease frequently affects the cardiovascular system as"/>
  <result pre="cardiovascular comorbidities. Although COVID-19 primarily disrupts the respiratory system, the" exact="disease" post="frequently affects the cardiovascular system as well, especially in"/>
  <result pre="primarily disrupts the respiratory system, the disease frequently affects the" exact="cardiovascular" post="system as well, especially in more severe cases. The"/>
  <result pre="in aÂ recent study of 671 severely ill COVID-19 patients" exact="acute" post="myocardial injury and acute heart failure were identified as"/>
  <result pre="of 671 severely ill COVID-19 patients acute myocardial injury and" exact="acute" post="heart failure were identified as death-related complications in 30.6%"/>
  <result pre="671 severely ill COVID-19 patients acute myocardial injury and acute" exact="heart" post="failure were identified as death-related complications in 30.6% and"/>
  <result pre="Of these patients, 98.4% had ARDS and 90.3% suffered from" exact="acute" post="respiratory failure. AÂ small percentage of hospitalised COVID-19 patients"/>
  <result pre="these patients, 98.4% had ARDS and 90.3% suffered from acute" exact="respiratory" post="failure. AÂ small percentage of hospitalised COVID-19 patients develop"/>
  <result pre="respiratory failure. AÂ small percentage of hospitalised COVID-19 patients develop" exact="cardiac disease" post="in the absence of marked pulmonary illness [86]. The"/>
  <result pre="failure. AÂ small percentage of hospitalised COVID-19 patients develop cardiac" exact="disease" post="in the absence of marked pulmonary illness [86]. The"/>
  <result pre="percentage of hospitalised COVID-19 patients develop cardiac disease in the" exact="absence of" post="marked pulmonary illness [86]. The cardiovascular complications of COVID-19"/>
  <result pre="COVID-19 patients develop cardiac disease in the absence of marked" exact="pulmonary" post="illness [86]. The cardiovascular complications of COVID-19 include acute"/>
  <result pre="disease in the absence of marked pulmonary illness [86]. The" exact="cardiovascular" post="complications of COVID-19 include acute myocardial injury, heart failure"/>
  <result pre="marked pulmonary illness [86]. The cardiovascular complications of COVID-19 include" exact="acute" post="myocardial injury, heart failure with or without cardiogenic shock,"/>
  <result pre="[86]. The cardiovascular complications of COVID-19 include acute myocardial injury," exact="heart" post="failure with or without cardiogenic shock, pericardial effusion with"/>
  <result pre="COVID-19 include acute myocardial injury, heart failure with or without" exact="cardiogenic shock," post="pericardial effusion with or without tamponade, arrhythmias and sudden"/>
  <result pre="acute myocardial injury, heart failure with or without cardiogenic shock," exact="pericardial effusion" post="with or without tamponade, arrhythmias and sudden cardiac death"/>
  <result pre="with or without tamponade, arrhythmias and sudden cardiac death and" exact="thrombosis" post="of small and large blood vessels [31, 87]. The"/>
  <result pre="and sudden cardiac death and thrombosis of small and large" exact="blood vessels" post="[31, 87]. The most common cardiac complication of COVID-19"/>
  <result pre="[31, 87]. The most common cardiac complication of COVID-19 is" exact="acute" post="myocardial injury, as evinced by increased plasma levels of"/>
  <result pre="51.2% versus 4.5% in patients without myocardial injury [88]. Moreover," exact="disease" post="severity and risk of death were positively correlated with"/>
  <result pre="natriuretic peptide levels [89], suggesting aÂ link between cardiac injury," exact="systemic" post="inflammation and myocardial wall stress. Multiple mechanisms may be"/>
  <result pre="link between cardiac injury, systemic inflammation and myocardial wall stress." exact="Multiple" post="mechanisms may be responsible for the myocardial injury observed"/>
  <result pre="erosion/rupture (i.e. obstructive coronary artery disease) induced by COVID-19-related hypoxaemia," exact="systemic" post="hyperinflammation or angiotensin-2/angiotensin-(1â€&quot;7)Â misbalance [66] leading to type 1Â"/>
  <result pre="systemic hyperinflammation or angiotensin-2/angiotensin-(1â€&quot;7)Â misbalance [66] leading to type 1Â" exact="myocardial infarction." post="The myocardial injury could also be caused by virus-"/>
  <result pre="could also be caused by virus- or immune-mediated myocarditis, stress-induced" exact="cardiomyopathy" post="or oxygen supply and demand mismatch resulting in type"/>
  <result pre="or oxygen supply and demand mismatch resulting in type 2Â" exact="myocardial infarction" post="(i.e. myocardial infarction without acute coronary syndrome), possible linked"/>
  <result pre="and demand mismatch resulting in type 2Â myocardial infarction (i.e." exact="myocardial infarction" post="without acute coronary syndrome), possible linked to respiratory insufficiency"/>
  <result pre="resulting in type 2Â myocardial infarction (i.e. myocardial infarction without" exact="acute" post="coronary syndrome), possible linked to respiratory insufficiency and/or sepsis."/>
  <result pre="(i.e. myocardial infarction without acute coronary syndrome), possible linked to" exact="respiratory" post="insufficiency and/or sepsis. Sepsis and the sepsis-related cytokine storm"/>
  <result pre="and the sepsis-related cytokine storm together with myocardial injury and" exact="ischaemia" post="are likely involved in the occurrence of cardiac arrhythmias"/>
  <result pre="to be largely responsible for the hypercoagulable state and consequential" exact="disseminated intravascular coagulation" post="/thrombotic microangiopathy and venous thrombosis including pulmonary embolism often"/>
  <result pre="state and consequential disseminated intravascular coagulation /thrombotic microangiopathy and venous" exact="thrombosis" post="including pulmonary embolism often seen in (severely ill/deceased) COVID-19"/>
  <result pre="consequential disseminated intravascular coagulation /thrombotic microangiopathy and venous thrombosis including" exact="pulmonary embolism" post="often seen in (severely ill/deceased) COVID-19 patients. Other factors"/>
  <result pre="in (severely ill/deceased) COVID-19 patients. Other factors contributing to the" exact="coagulopathy" post="could be endothelial damage due to (1)Â the hyperinflammatory"/>
  <result pre="cases, (2)Â disturbance of the angiotensin-2/angiotensin-(1â€&quot;7)Â balance and (3)Â SARS-CoVâ€‘2" exact="infection" post="of endothelial cells [81]. More extensive discussions about the"/>
  <result pre="infection of endothelial cells [81]. More extensive discussions about the" exact="cardiovascular" post="aspects of COVID-19 are provided in some recent reviews"/>
  <result pre="90, 91]. For information on how to manage the various" exact="cardiovascular" post="complications of the COVID-19 pandemic, see [92, 93] and"/>
  <result pre="serious threat to human health. The outcome of aÂ SARS-CoVâ€‘2" exact="infection" post="is highly variable and dependent on multiple factors, including"/>
  <result pre="highly variable and dependent on multiple factors, including SARS-CoVâ€‘2 genotype," exact="infectious" post="dose, genetic background, health status, immunological readiness and age."/>
  <result pre="status, immunological readiness and age. While COVID-19 is primarily aÂ" exact="respiratory" post="disease and mostly has aÂ mild course, in severe"/>
  <result pre="immunological readiness and age. While COVID-19 is primarily aÂ respiratory" exact="disease" post="and mostly has aÂ mild course, in severe cases"/>
  <result pre="in severe cases other organs are also affected, including the" exact="heart" post="and vasculature. To what extent the cardiovascular manifestations of"/>
  <result pre="affected, including the heart and vasculature. To what extent the" exact="cardiovascular" post="manifestations of COVID-19 are due to direct viral injury"/>
  <result pre="extent the cardiovascular manifestations of COVID-19 are due to direct" exact="viral" post="injury of cardiovascular cells or are an indirect consequence"/>
  <result pre="manifestations of COVID-19 are due to direct viral injury of" exact="cardiovascular" post="cells or are an indirect consequence of the extensive"/>
  <result pre="S A20191162714227150 4.TangDComishPKangRThe hallmarks of COVID-19 diseasePLoS Pathog202016e100853632442210 5.ChanJFYuanSKokKHet al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="hallmarks of COVID-19 diseasePLoS Pathog202016e100853632442210 5.ChanJFYuanSKokKHet al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="aÂ family clusterLancet202039551452331986261 6.ZhuNZhangDWangWet al.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med202038272773331978945 7.collab: Coronaviridae Study"/>
  <result pre="of the International Committee on Taxonomy of Viruses.The species severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat."/>
  <result pre="the International Committee on Taxonomy of Viruses.The species severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat. Rev."/>
  <result pre="and naming it SARS-CoV-2Nat. Rev. Microbiol.20205536544 8.LiuPJiangJZWanXFet al.Are pangolins the" exact="intermediate" post="host of the 2019 novel coronavirus (SARS-CoV-2)?PLoS Pathog202016e100842132407364 9.DomingoEPeralesCViral"/>
  <result pre="proteins of SARS-CoV and other coronavirusesAntiviral Res20141099710924995382 18.RussellTWHellewellJJarvisCIet al.Estimating the" exact="infection" post="and case fatality ratio for coronavirus disease (COVID-19) using"/>
  <result pre="18.RussellTWHellewellJJarvisCIet al.Estimating the infection and case fatality ratio for coronavirus" exact="disease" post="(COVID-19) using age-adjusted data from the outbreak on the"/>
  <result pre="death in the linked electronic health records of 17 million" exact="adult" post="NHS patients2020 20.DengGYinMChenXZengFClinical determinants for fatality of 44,672 patients"/>
  <result pre="COVID-19Crit Care20202417932345311 21.EllinghausDDegenhardtFBujandaLet al.Genomewide association study of severe COVID-19 with" exact="respiratory" post="failureN Engl J Med202010.1056/NEJMoa202028332558485 22.LiQGuanXWuPet al.Early transmission dynamics in"/>
  <result pre="novel coronavirus-infected pneumoniaN Engl J Med20203821199120731995857 23.HeXLauEHYWuPet al.Temporal dynamics in" exact="viral" post="shedding and transmissibility of COVID-19Nat Med20202667267510.1038/s41591-020-0869-532296168 24.AmirianESPotential fecal transmission"/>
  <result pre="al.SARS-CoV-2 productively infects human gut enterocytesScience202010.1126/science.abc166932631886 27.XiaoFTangMZhengXet al.Evidence for gastrointestinal" exact="infection" post="of SARS-CoV-2Gastroenterology20201581831183332142773 28.ShiJWenZZhongGet al.Susceptibility of ferrets, cats, dogs, and"/>
  <result pre="Ernest ShackletonThorax202010.1136/thoraxjnl-2020-21509132461231 30.WuZMcGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of aÂ report"/>
  <result pre="aÂ report of 72â€¯314 cases from the Chinese center for" exact="disease" post="control and preventionJAMA202010.1001/jama.2020.26487149375 31.PericÃ sJMHernandez-MenesesMSheahanTPet al.COVID-19: from epidemiology to"/>
  <result pre="control and preventionJAMA202010.1001/jama.2020.26487149375 31.PericÃ sJMHernandez-MenesesMSheahanTPet al.COVID-19: from epidemiology to treatmentEur" exact="Heart" post="J2020412092211232511724 32.PormohammadAGhorbaniSKhatamiAet al.Comparison of confirmed COVID-19 with SARS and"/>
  <result pre="status associations with cell type-specific expression of mediators of SARS-CoV-2" exact="viral" post="entry and highlights inflammatory programs in putative target cells2020"/>
  <result pre="al.Incubation period and other epidemiological characteristics of 2019 novel coronavirus" exact="infections" post="with right truncation: aÂ statistical analysis of publicly available"/>
  <result pre="ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 38.ZhouFYuTDuRet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: aÂ retrospective cohort"/>
  <result pre="China: aÂ retrospective cohort studyLancet20203951054106232171076 39.WongHYFLamHYSFongAHet al.Frequency and distribution of" exact="chest" post="radiographic findings in COVID-19 positive patientsRadiology201910.1148/radiol.202020116031746689 40.ShiHHanXJiangNet al.Radiological findings"/>
  <result pre="positive patientsRadiology201910.1148/radiol.202020116031746689 40.ShiHHanXJiangNet al.Radiological findings from 81 patients with COVID-19" exact="pneumonia" post="in Wuhan, China: aÂ descriptive studyLancet Infect Dis20202042543432105637 41.SunZZhangNLiYXuXA"/>
  <result pre="China: aÂ descriptive studyLancet Infect Dis20202042543432105637 41.SunZZhangNLiYXuXA systematic review of" exact="chest" post="imaging findings in COVID-19Quant Imaging Med Surg2020101058107932489929 42.BajJKarakuÅ‚a-JuchnowiczHTeresiÅ&quot;skiGet al.COVID-19:"/>
  <result pre="futureFront Public Health2020818910.3389/fpubh.2020.0018932574292 48.NeteaMGGiamarellos-BourboulisEJDomÃ­nguez-AndrÃ©sJet al.Trained immunity: aÂ tool for reducing" exact="susceptibility to" post="and the severity of SARS-CoV-2 infectionCell202018196997732437659 49.RisitanoAMMastellosDCHuber-LangMet al.Complement as"/>
  <result pre="T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19" exact="disease" post="and unexposed individualsCell20201811489150132473127 55.NiLYeFChengMLet al.Detection of SARS-CoV-2-specific humoral and"/>
  <result pre="immunity in COVID-19 convalescent individualsImmunity20205297197732413330 56.ChengMPPapenburgJDesjardinsMet al.Diagnostic testing for severe" exact="acute" post="respiratory syndrome-related coronavirus 2: aÂ narrative reviewAnn Intern Med202017272673432282894"/>
  <result pre="in COVID-19 convalescent individualsImmunity20205297197732413330 56.ChengMPPapenburgJDesjardinsMet al.Diagnostic testing for severe acute" exact="respiratory" post="syndrome-related coronavirus 2: aÂ narrative reviewAnn Intern Med202017272673432282894 57.VenterMRichterKTowards"/>
  <result pre="trialsInt J Mol Sci2020212657 61.VennemaHde GrootRJHarbourDAet al.Early death after feline" exact="infectious" post="peritonitis virus challenge due to recombinant vaccinia virus immunizationJ"/>
  <result pre="J Mol Sci2020212657 61.VennemaHde GrootRJHarbourDAet al.Early death after feline infectious" exact="peritonitis" post="virus challenge due to recombinant vaccinia virus immunizationJ Virol199064140714092154621"/>
  <result pre="death after feline infectious peritonitis virus challenge due to recombinant" exact="vaccinia" post="virus immunizationJ Virol199064140714092154621 62.DiamondMSPiersonTCThe challenges of vaccine development against"/>
  <result pre="opportunitiesClin Chim Acta202050825426632474009 66.de VriesAAFRenin-angiotensin system inhibition in COVID-19 patientsNeth" exact="Heart" post="J202010.1007/s12471-020-01439-532671650 67.PatilVMSinghalSMasandNA systematic review on use of aminoquinolines for"/>
  <result pre="al.The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against SARS-CoV-2" exact="infection" post="(COVID-19): aÂ role for iron homeostasis?Pharmacol Res202015810490432430286 69.BlochEMShohamSCasadevallAet al.Deployment"/>
  <result pre="and treatment of COVID-19J Clin Invest20201302757276532254064 70.LeeAJAshkarAAThe dual nature of" exact="type I" post="and type II interferonsFront Immunol20189206130254639 71.KindlerEThielVWeberFInteraction of SARS and"/>
  <result pre="COVID-19J Clin Invest20201302757276532254064 70.LeeAJAshkarAAThe dual nature of type I and" exact="type II" post="interferonsFront Immunol20189206130254639 71.KindlerEThielVWeberFInteraction of SARS and MERS coronaviruses with"/>
  <result pre="al.SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway" exact="epithelial" post="cells and is detected in specific cell subsets across"/>
  <result pre="ARBs, ACEIs and statins on clinical outcomes of 1 COVID-19" exact="infection" post="among nursing home residents2020 77.KlokFAKruipMJHAvan der MeerNJMet al.Confirmation of"/>
  <result pre="al.Anticoagulant treatment is associated with decreased mortality in severe coronavirus" exact="disease" post="2019 patients with coagulopathyJ Thromb Haemost2020181094109932220112 83.BikdeliBMadhavanMVJimenezDet al.COVID-19 and"/>
  <result pre="clinical significance of myocardial injury in patients with severe coronavirus" exact="disease" post="2019Eur Heart J2020412070207932391877 86.HendrenNSGrodinJLDraznerMHUnique patterns of cardiovascular involvement in"/>
  <result pre="of myocardial injury in patients with severe coronavirus disease 2019Eur" exact="Heart" post="J2020412070207932391877 86.HendrenNSGrodinJLDraznerMHUnique patterns of cardiovascular involvement in coronavirus disease-2019J"/>
  <result pre="with severe coronavirus disease 2019Eur Heart J2020412070207932391877 86.HendrenNSGrodinJLDraznerMHUnique patterns of" exact="cardiovascular" post="involvement in coronavirus disease-2019J Card Fail20202646646932417379 87.HendrenNSDraznerMHBozkurtBet al.Description and"/>
  <result pre="disease-2019J Card Fail20202646646932417379 87.HendrenNSDraznerMHBozkurtBet al.Description and proposed management of the" exact="acute" post="COVID-19 cardiovascular syndromeCirculation20201411903191432297796 88.ShiSQinMShenBet al.Association of cardiac injury with"/>
  <result pre="Fail20202646646932417379 87.HendrenNSDraznerMHBozkurtBet al.Description and proposed management of the acute COVID-19" exact="cardiovascular" post="syndromeCirculation20201411903191432297796 88.ShiSQinMShenBet al.Association of cardiac injury with mortality in"/>
  <result pre="89.GuoTFanYChenMet al.Cardiovascular implications of fatal outcomes of patients with coronavirus" exact="disease" post="2019 (COVID-19)JAMA202010.1001/jamacardio.2020.101732492084 90.DrigginEMadhavanMVBikdeliBet al.Cardiovascular considerations for patients, health care"/>
  <result pre="the COVID-19 pandemicJ Am Coll Cardiol2020752352237132201335 91.GuzikTJMohiddinSADimarcoAet al.COVID-19 and the" exact="cardiovascular" post="system: implications for risk assessment, diagnosis, and treatment optionsCardiovasc"/>
  <result pre="implications for risk assessment, diagnosis, and treatment optionsCardiovasc Res202010.1093/cvr/cvaa10632582932 92.DhakalBPSweitzerNKIndikJHAcharyaDWilliamPSARS-CoV-2" exact="infection" post="and cardiovascular disease: COVID-19 heartHeart Lung Circ202010.1016/j.hlc.2020.05.10132601020 93.GanatraSDaniSSShahSet al.Management"/>
  <result pre="risk assessment, diagnosis, and treatment optionsCardiovasc Res202010.1093/cvr/cvaa10632582932 92.DhakalBPSweitzerNKIndikJHAcharyaDWilliamPSARS-CoV-2 infection and" exact="cardiovascular" post="disease: COVID-19 heartHeart Lung Circ202010.1016/j.hlc.2020.05.10132601020 93.GanatraSDaniSSShahSet al.Management of cardiovascular"/>
  <result pre="and cardiovascular disease: COVID-19 heartHeart Lung Circ202010.1016/j.hlc.2020.05.10132601020 93.GanatraSDaniSSShahSet al.Management of" exact="cardiovascular disease" post="during coronavirus disease (COVID-19) pandemicTrends Cardiovasc Med202010.1016/j.tcm.2020.05.00432474135"/>
  <result pre="cardiovascular disease: COVID-19 heartHeart Lung Circ202010.1016/j.hlc.2020.05.10132601020 93.GanatraSDaniSSShahSet al.Management of cardiovascular" exact="disease" post="during coronavirus disease (COVID-19) pandemicTrends Cardiovasc Med202010.1016/j.tcm.2020.05.00432474135"/>
  <result pre="heartHeart Lung Circ202010.1016/j.hlc.2020.05.10132601020 93.GanatraSDaniSSShahSet al.Management of cardiovascular disease during coronavirus" exact="disease" post="(COVID-19) pandemicTrends Cardiovasc Med202010.1016/j.tcm.2020.05.00432474135"/>
 </snippets>
</snippetsTree>
